A Comprehensive Review of Nipah Virus: From Epidemics to Approaches of Management

Nipah virus (NiV) continues to remain a significant threat to health of the public, characterized by its ability to cause respiratory and neurological complications. The World Health Organization (WHO) has identified NiV as a priority disease for its R and D Blueprint. However, despite extensive res...

Full description

Saved in:
Bibliographic Details
Published in:Journal of pure & applied microbiology : an international research journal of microbiology 2024-09, Vol.18 (3), p.1502-1514
Main Authors: Pandey, Himanshu, Pandey, Pallavi, Jakhmola, Vikash, Semwal, Amit, Deorari, Mahamedha, Ansori, Arif Nur Muhammad, Zainul, Rahadian
Format: Article
Language:English
Subjects:
Analysis
Bangladesh
Care and treatment
Epidemics
India
Infection
Malaysia
Monoclonal antibodies
neurological
nipah virus
preventive measure
Public health
respiratory
RNA
treatment
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Nipah virus (NiV) continues to remain a significant threat to health of the public, characterized by its ability to cause respiratory and neurological complications. The World Health Organization (WHO) has identified NiV as a priority disease for its R and D Blueprint. However, despite extensive research efforts, specific antiviral therapies for NiV infection are currently unavailable. This highlights the crucial need to focus on supportive care for patients affected by the NiV. Therapies Prompt medical attention, including mechanical ventilation and intensive care, is crucial in case of NiV infection. Preventive measures such as avoiding consumption of raw date palm sap and implementing control of infection practices, gives a major role in halting the spread of NiV. This review provides a comprehensive overview of NiV, including its unique characteristics, clinical manifestations, diagnostic methods, treatment strategies, and preventive measures. The article also provides details on vaccines currently undergoing clinical trials, including ChAdOx1, PHV02, mRNA-1215, HeV-sG-V, and CD40.NiV. In addition, it highlights that the m102.4 monoclonal antibody and nucleotide analogue remdesivir has shown effective in the Non-Human Primate (NHP) model was also reviewed.
ISSN:0973-7510
2581-690X
DOI:10.22207/JPAM.18.3.33